Introduction
============

Despite progress in pain management, moderate-to-severe acute postoperative pain remains a problem, and has been formally recognized as such by several associations and societies worldwide, including the Agency for Health Care Policy and Research (AHCPR; US), the International Association of the Study of Pain, and the Royal College of Surgeons (UK) ([@b31]; [@b1]; [@b26]; [@b38]). According to the AHCPR, the ethical obligation to manage pain and relieve the patient's suffering is at the core of a healthcare professional's commitment, and anything harmful to the patient, including postoperative pain, should be minimized or prevented if possible ([@b1]). Acute pain has been associated with thromboembolic and pulmonary complications, additional time spent in the hospital, hospital readmission for further pain management, impairment in quality of life, and the potential to develop chronic pain ([@b3]). Acute pain not only adds undue physical and emotional stress to the patient, but it can also lead to increased healthcare costs ([@b38])

Patient-controlled analgesia (PCA) refers to a method of pain control that allows patients to self-administer small doses of an analgesic agent as required. Following titration to comfort (a score of ≤4 on a scale 0--10; 0 = no pain, 10 = worst possible pain) using a loading dose of an opioid administered intravenously, PCA allows the patient to control pain through self-administered, small, intermittent doses of an analgesic drug as needed ([@b20]). A study of 200 postsurgical patients demonstrated a high level of patient satisfaction with PCA, noting that control over pain was its most clinically significant feature (top response by 50.5% of patients) ([@b16]). Furthermore, there is some evidence of a decreased risk of postoperative pulmonary complications associated with PCA ([@b46]). Intravenous (IV) PCA using opioids is one of the most common methods of providing postoperative analgesia for the treatment of acute pain ([@b20]). Based on a meta-analysis of 32 randomized, controlled trials, intravenous opioid PCA provides better analgesia than conventional parenteral opioid regimens, without an increase in opioid-related side effects ([@b46]). While patient-controlled epidural analgesia (PCEA) offers many of the same benefits of IV PCA, patient preference study results indicated that patients prefer IV PCA to PCEA ([@b36]).

One of the most common PCA modalities for the management of acute postoperative pain is morphine sulfate IV PCA. Although this modality has dramatically improved postoperative pain management, there are limitations and potential safety concerns that may restrict its use ([@b44]). Nearly one quarter of the errors that commonly occur in post-anesthesia care units (PACUs) involve an improper dose of a medication, and PCA is one of the problem areas identified ([@b25]). The most significant risk when using PCA pumps is accidental overmedication leading to narcotic-induced respiratory depression. These pumps require programming by the clinician, introducing the possibility of complications, or even death, due to programming errors ([@b2]; [@b10]; [@b18]; [@b41]). Additional safety issues include possible drug product confusion, device design flaws, inadequate staff training, prescription errors, and complications such as IV-related phlebitis ([@b11]; [@b27]). A recent study of 122 IV drug preparations found that 4 (3%) had potentially severe errors in preparation and administration, 38 (31%) had potentially moderate errors, and 16 (13%) had potentially minor errors ([@b39]). PCA medical errors can be dangerous or even fatal ([@b17]), and the risk of errors associated with currently available modalities may limit their utility.

Furthermore, the IV PCA system requires a pump, line, tubing, power cables, and pole. These are not only time consuming to set up and maintain, but may also reduce patient mobility and interfere with physical therapy ([@b45]). In a recent study (N=77), the unwieldiness of this set up was one the most frequent reasons for IV PCA discontinuation (15.6%), second only to stopping treatment because the patient no longer experienced pain (51.9%) ([@b15]). Several new technologies offering alternative routes for PCA administration are being developed to address the limitations of current PCA techniques using IV administration.

The patient-controlled fentanyl HCl iontophoretic transdermal system (fentanyl ITS; IONSYS™, Janssen Pharmaceutica NV, Beerse, Belgium) ([Figure 1](#fig1){ref-type="fig"}) is a needle-free, self-contained drug-delivery system that uses iontophoretic technology to deliver fentanyl directly through the skin by application of a low-intensity electrical field ([@b14]). This review focuses on the technology, pharmacology, clinical efficacy, and safety of fentanyl ITS.

![The fentanyl hydrochloride iontophoretic transdermal system (fentanyl ITS).](tcrm0301-019-01){#fig1}

Fentanyl ITS: technology and design
===================================

Technology
----------

The fentanyl ITS uses non-invasive iontophoretic technology -- based on the electrotransport principle that similar charges repel each other -- to deliver fentanyl through the skin by application of an external electrical field. A battery is used to generate a current that flows from the anode to the cathode, forming a current loop between the system and the patient. As the anode surface becomes increasingly positively charged, the similarly positively charged drug molecules of fentanyl are forced out of the system across the skin. In addition to fentanyl, this process has been used for the transdermal delivery of a number of ionizable drugs such as lidocaine ([@b7]; [@b19]; [@b32]; [@b28]), morphine ([@b4]; [@b37]), and corticosteroids ([@b6]; [@b29]).

Although morphine sulfate is the most commonly used opioid for IV PCA, the properties of fentanyl make it an optimal candidate for iontophoretic drug delivery. Among the ideal properties of a drug for transdermal delivery are low molecular mass and high lipid solubility ([@b5]). Compared with morphine sulfate, fentanyl HCl has a lower molecular weight (372 Da vs 758 Da for morphine sulfate) and a higher lipophilicity ([@b30]). Fentanyl is approximately 100 times as potent as morphine ([@b8]), enters the central nervous system approximately 133 times as easily, and is metabolized to inactive metabolites (unlike morphine, which is metabolized to active metabolites that may be associated with neurotoxicity) ([@b30]; [@b40]). Combined with its rapid induction of analgesia and intermediate duration of action (terminal elimination half-life of 2--5 h) ([@b30]), these factors make fentanyl an ideal opioid for acute postoperative pain management via iontophoresis. Sufentanil could also be considered for administration via the transdermal route ([@b35]).

The optimal dosage of fentanyl for use with iontophoretic technology was determined based upon results of a randomized, double-blind, multicenter study conducted to evaluate the efficacy and safety of 3 doses of fentanyl (20 μg, 40 μg, or 60 μg delivered intravenously at a constant rate over 10 minutes with a maximum of 6 doses per hour) in 150 patients after major surgery ([@b12]). The primary efficacy endpoint was assessed by the number of positive responders, defined as a patient's global assessment score of "very good" or "excellent," plus the absence of severe adverse effects. Secondary endpoints included pain intensity, the number of valid and invalid demand doses (invalid demand doses were defined as requests in excess of the 6 doses/hour limit), and the investigator ratings. Patients in the 60 μg group had a significantly higher positive response rate (68%) compared with those of the 20 μg group (42%; p=0.011). However, there was no significant difference between the 40 μg group (52%) and the 60 μg or 20 μg groups. The investigator ratings paralleled those of patients. The number of invalid demands (indicating that patients were not receiving adequate pain relief \[[@b12]\]) were significantly higher for the 20 μg group (124 vs 74 \[40 μg group\] and 85 \[60 μg group\]; p\<0.05). Patients in the 60 μg group had significantly less pain at rest than those in the 20 μg and 40 μg groups (p=0.003 and p=0.03, respectively), and significantly less pain during movement than those in the 20 μg group (p=0.003). Although the 40 μg and 60 μg fentanyl doses provided equal analgesia based on the number of invalid demands, the 60 μg dose was associated with an increased risk of bradypnea. Taken together, these data suggest that the 40 μg dose of fentanyl provided the best combination of efficacy and safety for fentanyl ITS.

The amount of drug delivered via an iontophoretic system is correlated with the magnitude of the total electrical current ([@b21]; [@b24]; [@b23]). To determine the optimal current for fentanyl ITS, a randomized, open-label study (n=36) was conducted to investigate several fentanyl ITS prototypes with different current magnitude/anode area combinations, including 100 μA/1.38 cm^2^, 140 μA/2.72 cm^2^, 170 μA/2.75 cm^2^, 200 μA/2.75 cm^2^, and 230 μA/2.75 cm^2^ ([@b33]). The treatments from each prototype were administered as 2 consecutive 10-minute doses during the first 20 minutes of each hour for 23.33 h, with a single 10-minute dose at 23 h. The amount of fentanyl absorbed from fentanyl ITS was proportional to current for each 10-minute, on-demand dose and was estimated to be 24.8(±5.2) μg, 35.1(±12.1) μg, 39.5(±10.9) μg, 49.7(±8.8) μg, and 53.9(±12.8) μg for 100 μA/1.38 cm^2^, 140 μA/2.72 cm^2^, 170 μA/2.75 cm^2^, 200 μA/2.75 cm^2^, and 230 μA/2.75 cm^2^, respectively. Based on these results, 170 μA was considered the optimal current for delivery of the required 40 μg of fentanyl.

Design
------

The fentanyl ITS consists of 2 components housed within a single, compact, self-contained system that may be applied to the patient's upper outer arm or chest. The electromechanical component is located within the top housing and contains a printed circuit board and integrated circuit, transducer, capacitors, and lithium battery, as well as a recessed on-demand button and red light-emitting diode (LED). The drug component of the system consists of an anode hydrogel containing fentanyl HCl and a cathode hydrogel that contains no pharmacologically active ingredients. An adhesive on the outer edges of the unit allows the system to be attached to a patient's skin without the requirement for venous access. This completely self-contained, easy-to-use system eliminates the need for the pump, line, tubing, power cables, and pole associated with the use of IV PCA.

Based on dose-finding and electrical current studies ([@b12]; [@b21]; [@b24]; [@b23]; [@b33]), the fentanyl ITS has been pre-programmed to deliver fentanyl HCl 40 μg over a 10 min period with each system, providing a maximum of 6 doses per hour. When the patient presses the recessed on-demand button twice within 3 seconds, an electrical current passes through the fentanyl-containing anode hydrogel. The fentanyl is then ionized, and the positively charged drug molecules are repelled from the similarly positively charged anode surface. A system-initiated lockout prevents the patient from activating the system for additional drug delivery during the 10-minute infusion. The system operates for 24 h or delivers up to 80 doses, whichever occurs first. After this point, the system is inactivated and unresponsive to additional requests for medications. Therefore, the system has to be removed at the conclusion of the 24 h dosing period and a second system applied if continued analgesia is required.

A small light-emitting diode (LED) and audible beeps communicate the system's dosing status. When the patient initiates drug delivery by pressing the recessed on-demand button, an audible beep and a red light from the LED indicate that a dose has been initiated. After each dose is delivered, the LED flashes to indicate the cumulative number of doses a patient has received, with each flash representing up to 5 doses. Healthcare providers may query the system to display the approximate number of doses delivered at any time. Each LED flash represents 1--5 total doses administered, so 2 flashes represent 6--10 doses, 3 flashes represent 11--15 doses, and 16 flashes represent 76--80 doses administered.

Pharmacokinetics of fentanyl ITS
================================

Dosing frequency
----------------

Three randomized, open-label studies were performed to determine the effect of dosing frequency on the pharmacokinetics of fentanyl ITS ([@b34]). In the first study, 30 subjects received 3 fentanyl ITS 25 μg treatments, including 2 sequential doses hourly for 23.33 h (1A), 6 sequential doses every 3 h for 22 h (1B), and 72 doses continuously for 12 h (1C). All doses were delivered on demand over 10 minutes, and the area under the serum concentration-versus-time curves for a single dose (AUC~n~) were calculated by dividing AUC~23-24~ (for 1A), AUC~21-24~ (1B), and AUC~"~ (1C) by the number of doses in each dosing interval (2, 6, or 72 for 1A, 1B, and 1C, respectively). The AUC~n~ for 1A and 1B were similar (0.374 μg · h/L and 0.365 μg · h/L, respectively), suggesting that the bioavailability of fentanyl is independent of dosing frequency. Furthermore, the AUC~n~ for 1C, which had a shorter treatment duration than 1A and 1B, was significantly lower than 1A or 1B (0.314 μg · h/L; p=0.001), suggesting that bioavailability increases over time. The second study paralleled the first study, but investigated a 40 μg dose rather than a 25 μg dose ([@b34]). The conclusions of the second study were the same -- the bioavailability of fentanyl delivered via fentanyl ITS increased as a function of time and was independent of dosing frequency ([@b34]).

In the third study, 20 subjects received 4 fentanyl ITS 40 μg treatments, including 6 doses over 1 h (3A), 18 doses over 3 h (3B), 36 doses over 6 h (3C), and 80 doses over 13.33 h (3D) ([@b34]). Based on the dose-normalized AUC data, 41% of each nominal 40 μg dose was absorbed into the systemic circulation in the first hour of treatment, and increased to nearly 100% after 10 h. This delay in absorption over time is not clinically relevant (since patients self-administer medication according to their pain level) and may be due to alterations in the electrical conduction properties of the skin that may occur as it adjusts to the current input from fentanyl ITS ([@b34]).

Multi-day administration and comparison to fentanyl IV PCA
----------------------------------------------------------

Another study investigated the effects of single- and multiple-day administration on the pharmacokinetics of fentanyl delivered via fentanyl ITS, and compared the pharmacokinetics of fentanyl ITS versus fentanyl IV PCA ([@b33]). In the administration study, 28 subjects first received a single-day administration of two 10-minute doses of fentanyl 40 μg from the fentanyl ITS every 4 h for 20 h. This treatment was followed by a multiple-day administration of two 10-minute doses every 4 h for 68 h, with a new fentanyl ITS placed on a new skin site at 0 h, 24 h, and 48 h. Based on corrected AUC values of 0.40 μg · h/L and 0.54 μg · h/L for the single- and multiple-day treatments, respectively, there was no significant difference between study groups (p=0.133), and multiple-day administration did not alter the pharmacokinetics of fentanyl ITS ([@b33]). The results of the study comparing the pharmacokinetics of fentanyl ITS with fentanyl IV PCA (80 μg of IV fentanyl over 20 minutes compared with 2 consecutive 10-minute doses of 40 μg each from the fentanyl ITS) demonstrated that both modalities display similar pharmacokinetic profiles ([Table 1](#tbl1){ref-type="table"}). Additionally, the between-subject variability and decline in serum fentanyl concentration after completion of treatment were similar for both fentanyl ITS and fentanyl IV PCA modalities, suggesting that the use of fentanyl ITS is not associated with any greater variability in serum fentanyl concentration than would be seen with fentanyl IV PCA. After the fentanyl ITS is removed, the decline in serum fentanyl concentration is similar to IV PCA, suggesting negligible drug depot in the skin ([@b33]).

###### 

Pharmacokinetics of fentanyl hydrochloride iontophoretic transdermal system (ITS) versus fentanyl intravenous patient-controlled analgesia (IV PCA) ([@b33])[a](#tf1-1){ref-type="table-fn"}

                           Fentanyl ITS 40 μg (n=31)   Fentanyl IV PCA 80 μg (n=31)
  ------------------------ --------------------------- ------------------------------
  C~max~ (μg/L)            1.37                        1.82
  t~max~ (h)               0.65                        0.58
  t~1/2~ (h)               11.0                        12.6
  AUC~23--24~ (μg · h/L)   1.23                        1.34

80 μg of fentanyl was delivered via IV PCA over 20 min compared with 2 consecutive 10 min doses of 40 μg fentanyl each from the fentanyl ITS.

**Abbreviations**: AUC, area under serum concentration curve; C~max~, peak serum concentration; tmax, time to peak serum concentration; t~1/2~, half-life.

Effects of application site and subject demographics
----------------------------------------------------

The effects of application site and subject demographics on pharmacokinetics were also examined ([@b22]). The effect of application site was examined in a randomized study in which 34 subjects placed fentanyl ITS on the chest, upper outer arm, or lower inner arm. The results demonstrated a significantly lower AUC~23--24~ (AUC for 23--24 h) with application to the lower inner arm (0.757 μg · h/L) compared with the upper outer arm (1.033 μg · h/L; p=0.005) or chest (1.015 μg · h/L; p=0.013). To investigate the effects of subject demographics on the pharmacokinetics of fentanyl ITS, 70 subjects received fentanyl ITS 40 μg 3 times during the first 30 minutes of each hour for 3 h and were evaluated according to age, body weight, gender, and ethnicity ([@b22]). The results demonstrated that none of these demographic characteristics affected the pharmacokinetics of fentanyl delivered via fentanyl ITS.

Efficacy of fentanyl ITS
========================

The efficacy of fentanyl ITS in treating acute postoperative pain was first established in three phase 3 double-blind placebo-controlled clinical trials ([@b9]; [@b13]; [@b43]). The first of these trials was a 3:1 randomization study in which patients received either 40 μg of fentanyl HCl via fentanyl ITS over 10 minutes (n=76) or placebo (n=25) for the management of moderate-to-severe acute postoperative pain ([@b9]). Patients who received fentanyl ITS had lower dropout rates (7% vs 38%; p=0.001) ([Figure 2](#fig2){ref-type="fig"}) and lower pain intensity scores on a 100 mm visual analog scale (0 mm = no pain, 100 mm = worst possible pain; 28 vs 37; p=0.016) than control patients. The fentanyl ITS was also ranked as an "excellent" method of pain management by significantly more patients (65% vs 19%; p\<0.001) and investigators (62% vs 19%; p\<0.001) compared with placebo.

![Withdrawals due to inadequate analgesia in placebo-controlled trials ([@b9]; [@b13]; [@b43]).\
**Abbreviations:** fentanyl ITS, fentanyl hydrochloride iontophoretic transdermal system.](tcrm0301-019-02){#fig2}

A second, larger 3:1 randomization study assessed the efficacy of fentanyl ITS in 189 patients who underwent major abdominal, orthopedic, or thoracic surgery ([@b13]). Patients received a maximum of six 40 μg 10-minute doses of fentanyl ITS per hour for up to 24 h or 80 doses, whichever occurred first. Fewer patients who received fentanyl ITS withdrew from the trial because of inadequate analgesia after at least 3 h of treatment compared with placebo (25.4 % vs 40.4%; p\<0.05) ([Figure 2](#fig2){ref-type="fig"}). Patients treated with fentanyl ITS also reported lower (better) last pain intensity scores on a 100 mm visual analog scale (0 mm = no pain, 100 mm = worst possible pain; 30.9 vs 40.8; p=0.047). The global assessment of method of pain control was better for fentanyl ITS than placebo based on a 4-point categorical scale in which 1 = "poor" and 4 = "excellent" as judged by patients (3.0 vs 2.6; p=0.047) and investigators (3.1 vs 2.6; p=0.007). One limitation of this study, which could have minimized the observed efficacy, was that a greater proportion of patients (5:1) who received fentanyl ITS had high (≥75 on a 100 mm visual analog scale) baseline pain intensity scores, even though mean baseline pain scores between treatment groups were similar. This could have resulted in higher relative patient withdrawal because of inadequate analgesia in patients receiving fentanyl ITS compared with placebo. A third phase 3 study evaluating the efficacy of fentanyl HCl versus placebo addressed this limitation by setting a maximum baseline pain score for enrolled patients ([@b43]).

The findings of the largest placebo-controlled trial for fentanyl ITS were published in 2006 ([@b43]). In this study, 484 patients were treated with fentanyl ITS (n=244) or placebo (n=240) after major surgery. To minimize disproportionate baseline pain scores between groups, only patients with pain scores \<5 on an 11-point scale (0 = no pain, 10 = worst possible pain) were enrolled following initial IV opioid administration. Half as many patients treated with fentanyl ITS withdrew from the study because of inadequate analgesia compared with placebo (28.7% vs 60%; p\<0.0001) ([Figure 2](#fig2){ref-type="fig"}), and nearly twice as many patients were "very satisfied" with their pain management compared with placebo (61.5% vs 32.1%). The mean pain intensity scores of fentanyl-treated patients were significantly lower (better) throughout the 24 h treatment schedule, including the last pain intensity score on an 11-point scale (3.5 vs 5.4; p\<0.0001). The overall method of pain control was also described as "excellent" in those who received fentanyl ITS by significantly more patients (39.8% vs 14.6%; p\<0.0001) and investigators (47.5% vs 20.8%; p\<0.0001) compared with placebo.

In 2004, the results of the first study comparing the efficacy of fentanyl ITS with morphine IV PCA were published ([@b42]). In this prospective, parallel-group trial, 636 patients were assigned randomly to receive IV morphine (1 mg dose as a bolus, with a 5 min lockout and a maximum of 10 mg/h) by PCA pump (n=320) or fentanyl ITS (40 μg treatment over 10 min; n=316) ([@b42]). Most patients were female (72.5%), white (73.7%), and had undergone major abdominal, orthopedic, or thoracic surgery. Both modalities were therapeutically equivalent according to pain intensity scores at all assayed time points during the 24 h treatment period, and the distribution of patients' ratings of pain control as poor, fair, good, or excellent between treatment groups were not statistically different. Assessment of successful global pain management was determined by combining patients' ratings of pain control as good and excellent for each modality. These values were similar for fentanyl ITS and morphine IV PCA (73.7% and 76.9%, respectively; p=0.36) ([Figure 3](#fig3){ref-type="fig"}), further suggesting therapeutic equivalence between the 2 PCA systems.

![Percentage of patients rating pain control as "good" or "excellent" in the active-controlled trial ([@b42]).\
**Abbreviations:** fentanyl ITS, fentanyl hydrochloride iontophoretic transdermal system; IV, intravenous; PCA, patient-controlled analgesia.](tcrm0301-019-03){#fig3}

Safety and tolerability of fentanyl ITS
=======================================

To date, the safety and tolerability of fentanyl ITS have been examined in a total of 4 clinical studies ([@b9]; [@b13]; [@b42], [@b43]). Adverse events associated with fentanyl ITS are similar to those reported with IV opioid administration, including nausea, vomiting, pruritus, headache, and mild-to-moderate dizziness. Nausea was the most common adverse event, with the incidence ranging between 26.6% and 67.5%. In the active-comparator phase 3 trial, the incidence of nausea was similar between fentanyl ITS and IV morphine ([@b42]). Serious adverse events possibly related to fentanyl ITS included 1 case of severe urinary retention accompanied by moderate nausea and vomiting ([@b13]), 2 cases of ileus diagnosed after removal of fentanyl ITS ([@b43]), and 1 report of severe confusion ([@b42]). No patient treated with fentanyl ITS developed clinical respiratory depression (defined as the simultaneous occurrence of bradypnea \[respiratory rate \<8 breaths per minute\] and excessive sedation) in any of the 4 trials (n=778) ([@b9]; [@b13]; [@b42], [@b43]). Application-site skin reactions, such as erythema, rash, itching, and vesicles, were also observed in patients treated with fentanyl ITS, but their incidence was lower than 7% ([@b9]; [@b13]; [@b22]; [@b43]). Moreover, most of the application-site reactions were mild, resembling sunburn or tanning marks, and none required treatment ([@b43]).

Conclusions
===========

Findings from several controlled clinical studies indicate that fentanyl ITS is safe and effective for the management of acute postoperative pain. The fentanyl ITS allows patients to maintain an acceptable level of pain control following titration to comfort with a loading dose of opioid ([@b42]), while avoiding the first-pass effect and analgesic gaps associated with other pain management modalities. Patient satisfaction was demonstrated through the low number of withdrawals due to inadequate analgesia and the high percentage of patients rating pain control with fentanyl ITS as good or excellent. Furthermore, fentanyl ITS is the first needle-free, self-contained, patient-activated system developed for the management of acute postoperative pain, making it a safe, easy to use, and convenient modality of pain relief for both patients and healthcare professionals.
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